CN Patent

CN103002875A — Jak 抑制剂的局部用制剂

Assigned to Because Of C1-Esteraseremmer-N Parent Corp · Expires 2013-03-27 · 13y expired

What this patent protects

本发明涉及包含(R)-3-环戊基-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈或其药学上可接受的盐的用于局部皮肤施用的药物制剂，以及在治疗皮肤病症中的用途。

USPTO Abstract

本发明涉及包含(R)-3-环戊基-3-[4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基]丙腈或其药学上可接受的盐的用于局部皮肤施用的药物制剂，以及在治疗皮肤病症中的用途。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN103002875A
Jurisdiction: CN
Classification: —
Expires: 2013-03-27
Drug substance claim: No
Drug product claim: No
Assignee: Because Of C1-Esteraseremmer-N Parent Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.